These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 16690006)
1. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006 [TBL] [Abstract][Full Text] [Related]
2. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Blier P; Saint-André E; Hébert C; de Montigny C; Lavoie N; Debonnel G Int J Neuropsychopharmacol; 2007 Feb; 10(1):41-50. PubMed ID: 16690005 [TBL] [Abstract][Full Text] [Related]
3. Evidence of the dual mechanisms of action of venlafaxine. Harvey AT; Rudolph RL; Preskorn SH Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491 [TBL] [Abstract][Full Text] [Related]
4. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348 [TBL] [Abstract][Full Text] [Related]
5. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251 [TBL] [Abstract][Full Text] [Related]
6. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat. Béïque J; de Montigny C; Blier P; Debonnel G Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562 [TBL] [Abstract][Full Text] [Related]
7. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Béïque JC; de Montigny C; Blier P; Debonnel G Synapse; 1999 Jun; 32(3):198-211. PubMed ID: 10340630 [TBL] [Abstract][Full Text] [Related]
8. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
9. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Béïque JC; de Montigny C; Blier P; Debonnel G Br J Pharmacol; 1998 Oct; 125(3):526-32. PubMed ID: 9806336 [TBL] [Abstract][Full Text] [Related]
10. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Béïque J; de Montigny C; Blier P; Debonnel G Neuropharmacology; 2000 Jul; 39(10):1800-12. PubMed ID: 10884561 [TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Lenox-Smith AJ; Jiang Q Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525 [TBL] [Abstract][Full Text] [Related]
12. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291 [TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386 [TBL] [Abstract][Full Text] [Related]
14. A case of high-dose venlafaxine-related psychosis. Dennison EA; Raidoo BM; Cruz R; Raidoo D J Clin Psychopharmacol; 2013 Feb; 33(1):134-6. PubMed ID: 23288238 [No Abstract] [Full Text] [Related]
15. Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats. Vidal R; Valdizan EM; Vilaró MT; Pazos A; Castro E Br J Pharmacol; 2010 Oct; 161(3):695-706. PubMed ID: 20880406 [TBL] [Abstract][Full Text] [Related]
16. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. Millan MJ; Dekeyne A; Papp M; La Rochelle CD; MacSweeny C; Peglion JL; Brocco M J Pharmacol Exp Ther; 2001 Aug; 298(2):581-91. PubMed ID: 11454919 [TBL] [Abstract][Full Text] [Related]
18. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption. Shea ML; Garfield LD; Teitelbaum S; Civitelli R; Mulsant BH; Reynolds CF; Dixon D; Doré P; Lenze EJ Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607 [TBL] [Abstract][Full Text] [Related]
19. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Bymaster FP; Dreshfield-Ahmad LJ; Threlkeld PG; Shaw JL; Thompson L; Nelson DL; Hemrick-Luecke SK; Wong DT Neuropsychopharmacology; 2001 Dec; 25(6):871-80. PubMed ID: 11750180 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. Beyer CE; Boikess S; Luo B; Dawson LA J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]